Harmony Biosciences

Historical price data

Harmony Biosciences is a commercial-stage biopharmaceutical company with a mission to develop and commercialize therapies for rare neurological disorders through its patient-centric 'Newrology' model. Its foundational achievement was the 2019 FDA approval and subsequent successful commercialization of WAKIX® (pitolisant) for narcolepsy, which has propelled the company to profitability and a market valuation of $1.56B. The company's strategy involves leveraging its commercial engine and patient-focused insights to expand into adjacent rare neurological conditions, notably through the acquisitions of Zynerba Pharmaceuticals (2023) and Epygenix Therapeutics (2024) to build a pipeline in rare epilepsies. Harmony aims to become a leading, fully integrated rare neurology company, targeting over $1 billion in net revenue by 2026.

A patient-focused drug development model called 'Newrology,' which systematically integrates patient and caregiver insights into clinical research and commercialization to de-risk development and optimize market success.

In sleep/wake disorders, WAKIX competes with stimulants, sodium oxybate, and solriamfetol. In rare epilepsies, its acquired assets will compete in a crowded market with multiple approved cannabidiol and fenfluramine products. Harmony's key competitive advantage is its patient-centric commercial execution in complex rare neurology markets.